Adalvo has successfully launched the first and only Pregabalin Extended-Release (ER) tablets in Europe. This differentiated product has been introduced in two major European markets, Germany and Spain, through partnerships with two strategic collaborators.
Pregabalin ER is indicated for the treatment of neuropathic pain, offering a unique prolonged-release formulation that reduces the frequency of administration ensuring patient convenience and treatment compliance.
The European market for Pregabalin products reached $757 million in sales in 2023, according to IQVIA.
In the coming months, Adalvo plans to expand the availability of Pregabalin ER to additional leading European markets.
As the first and only company to launch Pregabalin ER in Europe, Adalvo has set a new benchmark in the pharmaceutical industry. Adalvo’s successful introduction of Pregabalin ER reflects our dedication to developing differentiated pharmaceutical products that meet specific patient needs.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!